Congress Asset Management’s Atea Pharmaceuticals AVIR Stock Holding History

Congress Asset Management’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-197,312	Closed	-$661K	–	375
2023 Q1	$661K	Buy	197,312 +19,400	+11%	+$78.7K	0.01%	317
2022 Q4	$856K	Buy	177,912 +2,039	+1%	+$10.3K	0.01%	314
2022 Q3	$1M	Buy	175,873 +1,830	+1%	+$14K	0.01%	302
2022 Q2	$1.24M	Sell	174,043 -7,092	-4%	-$48.4K	0.01%	308
2022 Q1	$1.31M	Buy	181,135 +13,449	+8%	+$91.3K	0.01%	309
2021 Q4	$1.5M	Sell	167,686 -15	-0%	-$234	0.01%	304
2021 Q3	$5.88M	Buy	167,701 +13,435	+9%	+$373K	0.05%	214
2021 Q2	$3.31M	Buy	154,266 +113,891	+282%	+$3.42M	0.03%	244
2021 Q1	$2.49M	Buy	40,375 +7,365	+22%	+$498K	0.02%	248
2020 Q4	$1.38M	Buy	+33,010	New	+$1.06M	0.01%	261

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Congress Asset Management's AVIR Position: Q2 2023 in Review

Congress Asset Management sold out of Atea Pharmaceuticals (AVIR) in Q2 2023, closing a stake of 197,312 shares — an estimated $661K sold.

Congress Asset Management first reported a position in AVIR in Q4 2020 and held it in 10 quarters. The position peaked at $5.88M in Q3 2021. 133 funds tracked by Wall St. Rank hold AVIR as of Q2 2023.

Congress Asset Management reported no remaining Atea Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Congress Asset Management sold 197,312 Atea Pharmaceuticals shares in Q2 2023, an estimated $661K.
Congress Asset Management first reported a position in Atea Pharmaceuticals in Q4 2020 and held it in 10 quarters.
Congress Asset Management's Atea Pharmaceuticals position peaked at $5.88M in Q3 2021.
133 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2023.

Based on Congress Asset Management's 13F filing for Q2 2023, filed 27 Jul 2023.